Comparing treatment strategies for MS starting after age 50
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial looks at two ways to treat multiple sclerosis (MS) that begins after age 50. It compares starting with a stronger medication right away versus starting with a milder one and then switching if needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting MS (RRMS) that started after your 50th birthday
- You began your first MS medication within 2 years of your first symptoms
- You are currently taking a moderately effective MS drug (like teriflunomide, dimethyl fumarate, glatiramer acetate, interferon beta) or a highly effective one (like fingolimod, natalizumab, ocrelizumab, cladribine)
- You do not have progressive MS from the start
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This study looks at whether it is safe for people aged 55 and older with stable multiple sclerosis to stop taking their MS medication. It compares stopping the medication versus continuing it, to see if stopping is safe and does not lead to new disease activity.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This study tests two oral medications, diroximel fumarate and dimethyl fumarate, in children and teens with relapsing MS. It aims to see if they are safe and can reduce the number of relapses compared to each other.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Hear when a new Multiple Sclerosis (MS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.